The FDA last week approved Amgen Inc.’s Kanjinto, a biosimilar to Roche’s Herceptin, for both of Herceptin’s oncology indications. For the treatment of breast cancer and gastric cancer, Herceptin holds preferred status for 10% of covered lives under the pharmacy benefit. It is not covered for 17% of lives.

SOURCE: MMIT Analytics, as of 6/17/19